FIELD: biotechnology; immunology; virology.
SUBSTANCE: group of inventions relates to biotechnology, immunology and virology. An expression vector based on the human adenovirus genome of serotype 19 has been created, containing: a constant sequence with deletion of E1 and E3 regions, inside which there is an expression cassette with the target gene; a variable region at the right end of the genome up to 1000 bp in size. In a particular embodiment of the expression vector, the constant sequence to the expression cassette has the sequence SEQ ID NO:1, and after the expression cassette has the sequence SEQ ID NO:2. The expression cassette as a vaccine antigen gene may contain SEQ ID NO:3, or SEQ ID NO:4, or SEQ ID NO:5, or SEQ ID NO:6, or SEQ ID NO:7. A method for obtaining an expression vector is also described, characterized in that it uses a shuttle plasmid containing a sequence that is homologous to a section of the adenovirus genome, the serotype of which differs from 19.
EFFECT: group of inventions provides the creation of an expression vector based on human adenovirus 19 serotype, which is capable of inducing an immune response to the vaccine antigen.
8 cl, 10 dwg, 5 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
Immunobiological agent and method of use thereof for inducing specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 (embodiments) | 2020 |
|
RU2720614C1 |
VACCINE AGAINST INFLUENZA TYPE A, INFLUENZA TYPE B AND COVID-19 | 2021 |
|
RU2751485C1 |
AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV-2) IN LIQUID FORM (VERSIONS) | 2021 |
|
RU2743963C1 |
IMMUNOBIOLOGICAL AGENT AND A METHOD FOR USE THEREOF FOR INDUCING SPECIFIC IMMUNITY TO THE MIDDLE EASTERN RESPIRATORY SYNDROME VIRUS (VERSIONS) | 2018 |
|
RU2709659C1 |
EXPRESSION VECTOR BASED ON HUMAN ADENOVIRUS 5 SEROTYPE, INDUCING CROSS-PROTECTIVE IMMUNITY TO INFLUENZA A VIRUSES OF SUBTYPE H1, AND A PHARMACEUTICAL COMPOSITION BASED ON IT | 2023 |
|
RU2802753C1 |
DRUG APPLICATION FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN CHILDREN | 2021 |
|
RU2761904C1 |
IMMUNOBIOLOGICAL AGENT AND METHOD FOR ITS USE FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST VIRUSES SARS-COV-2 VARIANT B.1.617.2 (DELTA) AND SARS-COV-2 VARIANT B.1.1.529 (OMICRON) (VARIANTS) | 2022 |
|
RU2779634C1 |
EXPRESSION VECTOR BASED ON HUMAN ADENOVIRUS SEROTYPE 5 INDUCING CROSS-PROTECTIVE IMMUNITY TO INFLUENZA A SUBTYPE H3 VIRUSES AND PHARMACEUTICAL COMPOSITION BASED ON IT | 2023 |
|
RU2814189C1 |
AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV-2) IN LYOPHILIZED FORM (VERSIONS) | 2021 |
|
RU2743962C1 |
IMMUNOBIOLOGICAL AGENT FOR INDUCING IMMUNE RESPONSE AGAINST SARS-COV-2 AND METHOD FOR USING IT (VERSIONS) | 2021 |
|
RU2765729C1 |
Authors
Dates
2024-01-17—Published
2023-04-16—Filed